Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Mucosal Immunology|June 18, 2010
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccinationB S Graham, R C Kines, K S Corbett, et al.
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
Critical Care Medicine|May 13, 1999
Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study GroupM M Arons, A P Wheeler, G R Bernard, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
The Journal of Infectious Diseases|April 1, 1988
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virusR M Hendry, J C Burns, E E Walsh, et al.
Journal of Clinical Microbiology|November 1, 1986
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infectionB R Murphy, D W Alling, M H Snyder, et al.
The New England Journal of Medicine|March 27, 1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study GroupG R Bernard, A P Wheeler, J A Russell, et al.
Clinical and Vaccine Immunology : CVI|September 8, 2012
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humansJ E Ledgerwood, Z Hu, I J Gordon, et al.
AIDS Research and Human Retroviruses|May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation GroupM C Keefer, B S Graham, M J McElrath, et al.
Pageof 16